New obesity pill enters human safety testing
NCT ID NCT06982131
First seen Jun 25, 2026 · Last updated Aug 06, 2026 · Updated 5 times
Summary
This early-stage study tests an experimental oral drug called RO7795081 in 40 healthy overweight or obese adults. The main goals are to check safety and how the drug interacts with common statins (rosuvastatin and pitavastatin). Participants will receive the drug or a placebo in multiple phases, and researchers will monitor side effects and drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RO7795081 (also called CT-996 or RG6652)
- What this could lead to
- If successful, this could lead to a new oral medication for weight management that may be used alongside statins.
- What could go wrong
- This is a very early Phase 1 safety study with only 40 participants, so it may not show effectiveness or could reveal safety issues. Results may not apply to the general population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICON Plc (LPRA) - Netherlands
RECRUITINGGroningen, 9728 NZ, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?